BioArctic company profile

BIOA.B · Nasdaq Stockholm · SEK

Compare BioArctic
kr 300.60Change from previous close: −1.83%Absolute change: −kr 5.60

Close · November 20, 2026

Company profile

BioArctic has 150 employees and is headquartered in Stockholm, Sweden.

Employing 150 people, the Stockholm-based biotech develops antibody drugs aimed at brain and nerve diseases. Its most advanced asset is lecanemab, which it offers as an intravenous treatment while developing a subcutaneous version, and a further lecanemab study is in Phase 3 testing for patients before symptoms appear. Other programmes target Alzheimer's, Parkinson's and ALS, and preclinical and research-stage projects cover additional central nervous system targets. Partnerships include a research agreement with Eli Lilly built around its BrainTransporter technology and a collaboration with Mesenkia Therapeutics on glioblastoma, a highly aggressive brain cancer.

In the fiscal year ended 31 December 2025, revenue reached 2.0 billion SEK and net income 1.0 billion SEK. The company had 150 employees at that time. BioArctic was incorporated in 2000, was formerly known as BioArctic Neuroscience AB, and adopted its current name in 2016. Its headquarters are in Stockholm, Sweden.

Company facts

Industry
Biotechnology
Country
Sweden
Headquarters
Warfvinges vag 35, 112 51, Stockholm
Employees
150
Chief executive
Gunilla Osswald
Founded
2000
Fiscal year
January - December
Listing
BIOA.B · Nasdaq Stockholm
Currency
SEK
ISIN
SE0010323311

BioArctic and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
BioArcticBIOA.BSweden$2.66B15019.6%259.5
Bavarian NordicBAVADenmark$2.72B1,92318.1%12.7
Zealand PharmaZEALDenmark$2.05B60559.0%4.76
Lakefront BiotherapeuticsLKFTNetherlands$2.19B19657.5%2.53
CamurusCAMXSweden$4.32B32337.4%58.7
IdorsiaIDIASwitzerland$1.26B424-68.4%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare BioArctic with its competitors